Company profile for Imara

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Imara is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies. Our pipeline is built on the differentiated therapeutic potential of our initial product candidate, IMR-687, which is an oral, once-a-day, highly selective, potent small molecule inhibitor of PDE9 in devel...
Imara is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies. Our pipeline is built on the differentiated therapeutic potential of our initial product candidate, IMR-687, which is an oral, once-a-day, highly selective, potent small molecule inhibitor of PDE9 in development for sickle cell disease and beta-thalassemia. Sickle cell disease and beta-thalassemia have limited treatment options and are both characterized by severe symptoms and effects and reduced life expectancy.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
116 Huntington Ave., 6th Floor | Boston, MA 02116
Telephone
Telephone
+1 617-206-2020
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2023/02/22/2613692/0/en/Imara-Announces-Stockholder-Approval-of-Merger-With-Enliven.html

GLOBENEWSWIRE
22 Feb 2023

https://www.biopharmadive.com/news/enliven-imara-reverse-merger-deal-public-market/634151/

Jacob Bell BIOPHARMADIVE
15 Oct 2022

https://www.globenewswire.com/news-release/2022/10/13/2534321/0/en/Enliven-Therapeutics-and-Imara-Announce-Merger-Agreement.html

GLOBENEWSWIRE
13 Oct 2022

https://endpts.com/imara-sells-failed-blood-disorder-drug-to-heart-disease-outfit-cardurion/

Lei Lei Wu ENDPTS
10 Sep 2022

https://finance.yahoo.com/finance/news/disappointing-data-imara-offloads-sickle-130541406.html

Vandana Singh YAHOO
08 Sep 2022
Imara to reduce staff by 83% amid biotech shakeout
Imara to reduce staff by 83% amid biotech shakeout

19 Apr 2022

// B. Fidler BIOPHARMADIVE

https://www.biopharmadive.com/news/imara-layoffs-sickle-cell-drug-biotech-downturn/622176/

B. Fidler BIOPHARMADIVE
19 Apr 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty